1
|
Perez-Gracia JL, Penel N, Calvo E, Arkenau HT, Amaral T, Grünwald V, Sanmamed MF. Reply to letter to the editor "Bureaucracy or Streamlining the Rules in "Good Clinical Practice (GCP)" - Has Equipoise Occurred?" by H. K. Kotikonda, V. G. Jonnalagadda and S. R. Venna. Ann Oncol 2023; 34:498-499. [PMID: 37121610 DOI: 10.1016/j.annonc.2023.02.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2023] [Accepted: 02/08/2023] [Indexed: 05/02/2023] Open
Affiliation(s)
- J L Perez-Gracia
- Department of Oncology, University Clinic of Navarra and Health Research Institute of Navarra (IdiSNA), Pamplona, Spain.
| | - N Penel
- Centre Oscar Lambret, Lille, France; Medical School, Lille University, Lille, France
| | - E Calvo
- START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain
| | | | - T Amaral
- Division of Dermato-oncology, Department of Dermatology, University of Tuebingen, Tuebingen, Germany; Cluster of Excellence iFIT (EXC 2180) "Image Guided and Functionally Instructed Tumor Therapies", Tuebingen, Germany
| | - V Grünwald
- University Hospital Essen, Clinic for Medical Oncology and Clinic for Urology, Essen, Germany
| | - M F Sanmamed
- Department of Oncology, University Clinic of Navarra and Health Research Institute of Navarra (IdiSNA), Pamplona, Spain
| |
Collapse
|
2
|
Perez-Gracia JL, Penel N, Calvo E, Awada A, Arkenau HT, Amaral T, Grünwald V, Sanmamed MF, Castelo-Branco L, Bodoky G, Lolkema MP, Di Nicola M, Casali P, Giuliani R, Pentheroudakis G. Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials. Ann Oncol 2023; 34:70-77. [PMID: 36209982 DOI: 10.1016/j.annonc.2022.09.162] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2022] [Revised: 09/22/2022] [Accepted: 09/28/2022] [Indexed: 02/03/2023] Open
Abstract
BACKGROUND During recent years, the burden of bureaucracy in clinical research has increased dramatically, adversely impacting the activity of investigators and clinical research teams. Although compliance with the Declaration of Helsinki, the guidelines for Good Clinical Practice (GCP), and other applicable regulations remains unquestionable, their overinterpretation and substitution by the internal operating procedures of sponsors and Contract Research Organizations (CROs) have increased the administrative burden. A survey conducted by the European Society for Medical Oncology (ESMO) Clinical Research Observatory (ECRO) among 940 investigators confirmed that they considered that the administrative burden in clinical research is excessive; that administrative procedures could be reduced without affecting the safety and the rights of the patients and the quality of the data; and that bureaucracy represents an obstacle for clinical research. METHODS A panel of physicians with extensive experience in clinical research, composed by members of the ECRO and the ESMO Scientific Medical and Public Policy divisions, analyzed clinical trial procedures related to administrative workflow, pharmacovigilance, and medical care. RESULTS The panel identified situations that generate debate between investigators and sponsors/CROs and selected real clinical scenarios that exemplify such situations. The panel discussed and proposed specific recommendations for those situations, based on GCP. CONCLUSIONS This initiative aspires to streamline clinical research procedures and to become a platform for discussion among all clinical trial stakeholders, with the aim of promoting the sustainability of clinical research and the care of cancer patients.
Collapse
Affiliation(s)
- J L Perez-Gracia
- Department of Oncology, University Clinic of Navarra and Health Research Institute of Navarra (IdiSNA), Pamplona, Spain.
| | - N Penel
- Centre Oscar Lambret and Lille University, Lille, France
| | - E Calvo
- START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain
| | - A Awada
- Institut Jules Bordet, Université Libre de Bruxelles (Head of the Oncology Medicine Department), Brussels, Belgium
| | | | - T Amaral
- Division of Dermato-Oncology, Department of Dermatology, University of Tuebingen, Tuebingen, Germany; Cluster of Excellence iFIT (EXC 2180) 'Image Guided and Functionally Instructed Tumor Therapies', Tuebingen, Germany
| | - V Grünwald
- University Hospital Essen, Clinic for Medical Oncology and Clinic for Urology, Essen, Germany
| | - M F Sanmamed
- Department of Oncology, University Clinic of Navarra and Health Research Institute of Navarra (IdiSNA), Pamplona, Spain
| | - L Castelo-Branco
- Scientific and Medical Division, ESMO - European Society for Medical Oncology, 6900 - Lugano, Switzerland; NOVA National School of Public Health, NOVA University, Lisbon, Portugal
| | | | - M P Lolkema
- Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands
| | - M Di Nicola
- Immunotherapy and Innovative Therapeutics Unit, Oncology and Hematology Department Fondazione, IRCCS Istituto Nazionale Tumori, Milan, Italy
| | - P Casali
- Fondazione IRCCS Istituto Nazionale Tumori and University of Milan, Milan, Italy
| | - R Giuliani
- The Clatterbridge Cancer Centre, Liverpool, UK
| | - G Pentheroudakis
- Scientific and Medical Division, European Society for Medical Oncology, Lugano, Switzerland
| |
Collapse
|
3
|
Formica V, Morelli C, Patrikidou A, Shiu KK, Nardecchia A, Lucchetti J, Roselli M, Arkenau HT. A systematic review and meta-analysis of PD-1/PD-L1 inhibitors in specific patient subgroups with advanced gastro-oesophageal junction and gastric adenocarcinoma. Crit Rev Oncol Hematol 2021; 157:103173. [PMID: 33278677 DOI: 10.1016/j.critrevonc.2020.103173] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2019] [Revised: 08/27/2020] [Accepted: 11/05/2020] [Indexed: 01/15/2023] Open
Abstract
BACKGROUND immune checkpoint inhibitors(ICIs) have shown contradictory results in patients with advanced gastro-oesophageal junction/gastric cancer(GOJ/GC). AIM to identify specific patient subgroups that would derive survival benefit from ICIs. METHODS a subgroup meta-analysis of randomised clinical trials(RCTs) was carried out. RESULTS four phase-III-RCTs were identified with data on the following variables: primary location(Gastric vs GOJ); age(≤ 65 vs >65); gender(male vs female); ECOG PS(0 vs 1); ethnicity (Asian vs non-Asian), histology(intestinal vs diffuse), PD-L1 expression(≥ 1% vs < 1%). PD-L1 positivity was significantly associated with survival benefit from ICIs (HR: 0.82, p 0.047), with a significant interaction between PD-L1 expression and ICI efficacy (interaction HR: 1.41, p 0.02). Numerically, the second most relevant interaction was ICI efficacy and gender, with ICI being more effective in males. CONCLUSION The PD-L1 positive patient subgroup derives significant survival benefit from ICI in GOJ/GC, however other predictors are eagerly needed to further refine patient selection.
Collapse
Affiliation(s)
- V Formica
- Medical Oncology Unit, Tor Vergata University Hospital, Viale Oxford 81, Rome, Italy.
| | - C Morelli
- Medical Oncology Unit, Tor Vergata University Hospital, Viale Oxford 81, Rome, Italy
| | - A Patrikidou
- Medical Oncology, Sarah Cannon Research Institute UK, London, UK
| | - K K Shiu
- Department of Oncology, University College Hospital, 235 Euston Road, London, NW1 2BU, UK
| | - A Nardecchia
- Medical Oncology Unit, Tor Vergata University Hospital, Viale Oxford 81, Rome, Italy
| | - J Lucchetti
- Medical Oncology Unit, Tor Vergata University Hospital, Viale Oxford 81, Rome, Italy
| | - M Roselli
- Medical Oncology Unit, Tor Vergata University Hospital, Viale Oxford 81, Rome, Italy
| | - H T Arkenau
- Medical Oncology, Sarah Cannon Research Institute UK, London, UK
| |
Collapse
|
4
|
Formica V, Morelli C, Patrikidou A, Shiu KK, Roselli M, Arkenau HT. Lymph node-only metastatic gastric/gastroesophageal junction cancer and efficacy of immunotherapy. Gastric Cancer 2020; 23:1107-1108. [PMID: 32424650 DOI: 10.1007/s10120-020-01084-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/30/2020] [Accepted: 05/06/2020] [Indexed: 02/07/2023]
Affiliation(s)
- V Formica
- Medical Oncology Unit and PhD program in Systems and Experimental Medicine (XXXV cycle), Tor Vergata University Hospital, Viale Oxford, 81, 00133, Rome, Italy.
| | - C Morelli
- Medical Oncology Unit and PhD program in Systems and Experimental Medicine (XXXV cycle), Tor Vergata University Hospital, Viale Oxford, 81, 00133, Rome, Italy
| | - A Patrikidou
- Drug Development Unit, Sarah Cannon Research Institute UK, London, UK.,Department of Oncology, University College Hospital, 235 Euston Road, London, NW1 2BU, UK
| | - K K Shiu
- Department of Oncology, University College Hospital, 235 Euston Road, London, NW1 2BU, UK
| | - M Roselli
- Medical Oncology Unit and PhD program in Systems and Experimental Medicine (XXXV cycle), Tor Vergata University Hospital, Viale Oxford, 81, 00133, Rome, Italy
| | - H T Arkenau
- Drug Development Unit, Sarah Cannon Research Institute UK, London, UK.,Department of Oncology, University College Hospital, 235 Euston Road, London, NW1 2BU, UK
| |
Collapse
|
5
|
Tabernero J, Shitara K, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, Alsina M, Ghidini M, Faustino C, Gorbunova V, Zhavrid E, Nishikawa K, Hosokawa A, Ganea D, Yalçın Ş, Fujitani K, Beretta G, Winkler R, Makris L, Doi T, Ilson D. Overall survival results from a phase III trial of trifluridine/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy208.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
|
6
|
Soria JC, Gan HK, Blagden SP, Plummer R, Arkenau HT, Ranson M, Evans TRJ, Zalcman G, Bahleda R, Hollebecque A, Lemech C, Dean E, Brown J, Gibson D, Peddareddigari V, Murray S, Nebot N, Mazumdar J, Swartz L, Auger KR, Fleming RA, Singh R, Millward M. A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. Ann Oncol 2016; 27:2268-2274. [PMID: 27733373 DOI: 10.1093/annonc/mdw427] [Citation(s) in RCA: 97] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2016] [Revised: 08/30/2016] [Accepted: 08/31/2016] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Focal adhesion kinase (FAK) is important in cancer growth, survival, invasion, and migration. The purpose of this study was to determine the maximum tolerated dose (MTD), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the FAK inhibitor, GSK2256098, in cancer patients. PATIENTS AND METHODS The dose of GSK2256098 was escalated, in cohorts of patients with advanced cancer, from 80 to 1500 mg, oral twice daily (BID), until the MTD was determined. Serial blood samples were obtained from all patients, and the PK was determined. Paired tumor biopsies were obtained in select patients, and the level of phospho-FAK (pFAK) was determined. RESULTS Sixty-two patients (39 males, 23 females; median age 61 y.o., range 21-84) received GSK2256098. Dose-limiting toxicities of grade 2 proteinuria (1000 mg BID), grade 2 fatigue, nausea, vomiting (1250 mg BID), and grade 3 asthenia and grade 2 fatigue (1500 mg BID) were reported with the MTD identified as 1000 mg BID. The most frequent adverse events (AEs) were nausea (76%), diarrhea (65%), vomiting (58%), and decreased appetite (47%) with the majority of AEs being grades 1-2. The PK was generally dose proportional with a geometric mean elimination half-life range of 4-9 h. At the 750, 1000, and 1500 mg BID dose levels evaluated, the pFAK, Y397 autophosphorylation site, was reduced by ∼80% from baseline. Minor responses were observed in a patient with melanoma (-26%) and three patients with mesothelioma (-13%, -15%, and -17%). In the 29 patients with recurrent mesothelioma, the median progression-free survival was 12 weeks with 95% CI 9.1, 23.4 weeks (23.4 weeks merlin negative, n = 14; 11.4 weeks merlin positive, n = 9; 10.9 weeks merlin status unknown, n = 6). CONCLUSIONS GSK2256098 has an acceptable safety profile, has evidence of target engagement at doses at or below the MTD, and has clinical activity in patients with mesothelioma, particularly those with merlin loss.
Collapse
Affiliation(s)
- J C Soria
- Drug Development Department at Gustave Roussy Cancer Campus, University Paris-Sud, Paris, France
| | - H K Gan
- Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Australia
- School of Cancer Medicine, Latrobe University, Melbourne, Australia
| | - S P Blagden
- Imperial College, Hammersmith Hospital, London
| | - R Plummer
- Northern Centre for Cancer Care, Newcastle
| | | | - M Ranson
- University of Manchester, Christie Hospital, Manchester
| | - T R J Evans
- University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK
| | - G Zalcman
- Early Phases Clinical Trials Unit at Caen University Hospital, Caen, France
| | - R Bahleda
- Drug Development Department at Gustave Roussy Cancer Campus, University Paris-Sud, Paris, France
| | - A Hollebecque
- Drug Development Department at Gustave Roussy Cancer Campus, University Paris-Sud, Paris, France
| | - C Lemech
- Sarah Cannon Research Institute, London
| | - E Dean
- University of Manchester, Christie Hospital, Manchester
| | - J Brown
- University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK
| | - D Gibson
- GlaxoSmithKline, Research Triangle Park, NC and Upper Providence, Collegeville, USA
| | - V Peddareddigari
- GlaxoSmithKline, Research Triangle Park, NC and Upper Providence, Collegeville, USA
| | - S Murray
- GlaxoSmithKline, Research Triangle Park, NC and Upper Providence, Collegeville, USA
| | - N Nebot
- GlaxoSmithKline, Research Triangle Park, NC and Upper Providence, Collegeville, USA
| | - J Mazumdar
- GlaxoSmithKline, Research Triangle Park, NC and Upper Providence, Collegeville, USA
| | - L Swartz
- GlaxoSmithKline, Research Triangle Park, NC and Upper Providence, Collegeville, USA
| | - K R Auger
- GlaxoSmithKline, Research Triangle Park, NC and Upper Providence, Collegeville, USA
| | - R A Fleming
- GlaxoSmithKline, Research Triangle Park, NC and Upper Providence, Collegeville, USA
| | - R Singh
- GlaxoSmithKline, Research Triangle Park, NC and Upper Providence, Collegeville, USA
| | - M Millward
- School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Perth, Australia
| |
Collapse
|
7
|
Nebot N, Arkenau HT, Infante JR, Chandler JC, Weickhardt A, Lickliter JD, Sarantopoulos J, Gordon MS, St-Pierre A, Tang L, Mookerjee B, Carson SW, Grossmann KF. Evaluation of the effect of dabrafenib on QTc interval in patients with BRAF V600–mutant tumors. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e14119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Noelia Nebot
- Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - HT Arkenau
- Sarah Cannon Research Institute and University College London, London, United Kingdom
| | | | | | - Andrew Weickhardt
- Olivia Newton-John Cancer and Wellness Centre, Austin Health, Heidelberg, Australia
| | | | - John Sarantopoulos
- Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center San Antonio, San Antonio, TX
| | - Michael S. Gordon
- Pinnacle Oncology Hematology/HonorHealth Research Institute, Scottsdale, AZ
| | | | - Lihua Tang
- Novartis Pharmaceuticals Corporation, Morrisville, NC
| | | | | | | |
Collapse
|
8
|
Baird RD, Cresti N, Beddowes E, Saggese M, Flynn M, Garcia Corbacho J, Gao F, Lemech C, Donaldson K, Posner J, Kawabata I, Forster M, Arkenau HT, Plummer R, Jodrell D, Spicer J. Abstract P4-12-24: Phase I trial of S-222611, a dual tyrosine kinase inhibitor of EGFR and HER2, with preliminary evidence of efficacy in patients (pts) with heavily-pretreated HER2-positive metastatic breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p4-12-24] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background and rationale: S-222611 is a novel, oral, reversible inhibitor of EGFR, HER2 and HER4 with an improved preclinical profile compared with first-generation pan-HER inhibitors.
Research objectives: We conducted a phase I study to determine safety, maximum tolerated dose (MTD), pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy in pts with solid tumors expressing EGFR or HER2.
Patients and methods: Pts with advanced solid tumors and biopsies confirming EGFR and/or HER2 expression were treated with continuous daily oral doses of S-222611. The dose of S-222611 was escalated in cohorts of at least 3 pts from 100mg to 1600mg. PK profiles were obtained in all pts, and PD assays for pEGFR, pHER2 and pHER3 were performed on paired tumor biopsies in selected pts.
Results: A total of 50 pts have been treated to-date; age 25-80y; 20 female; 13 with HER2-positive metastatic breast cancer (HER2+ MBC). S-222611 was generally well tolerated with two dose-limiting toxicities in the dose-escalation phase: rash at 1200mg; diarrhea at 1600mg. MTD was not defined. Diarrhea was the most frequent toxicity, but was rarely worse than grade 1/2. Nausea, rash, anorexia and fatigue were also seen. Bilirubin rises with normal transaminases were observed. Plasma concentrations of S-222611 increased with dose up to 800mg, which was the dose selected for the expansion phase. Steady state values of Cmax and AUC0-24 at this dose were in the effective range of concentrations in mouse models. Average t½ of 33h was consistent with once daily dosing. Tumor responses were seen over the full dose range tested (100-1600mg), with four pts on treatment for >12 months. Out of 13 HER2+ MBC pts, one clinical complete response (CR) was observed for >12 months, and four partial responses (PRs) were also seen (2 confirmed, 2 unconfirmed), yielding an overall response rate of 38% in this small group (Table 1). All 5 responding patients had previously progressed on trastuzumab (T); 4 of them had also progressed on lapatinib (L); and one patient had progressed on T, L and T-DM1. Out of 6 breast patients with PD results available, the 3 pts with a decrease in pHER3 all responded, whereas the 3 pts with no change or increase in pHER3 all had disease progression.
Conclusion: S-222611 was well tolerated in doses up to 1600mg daily with diarrhea, nausea and rash being readily manageable. Significant antitumor activity has been observed in patients with heavily pre-treated HER2+ MBC, including those progressing on prior T, L and T-DM1. Rates of grade 3 diarrhea appear markedly lower than those reported for other second-generation pan-HER TKIs. The recommended phase 2 dose, based on PK and clinical activity, is 800mg/day.
Table 1. HER2+ MBC pts with tumor shrinkage after S-222611 treatmentPatient numberPrior progression on trastuzumab-based regimenPrior progression on lapatinib-based regimenBest responseMonths on treatment (at time of data lock)S01014YYclinical CR20.3m (ongoing)S03034YNconfirmed PR11.5m (ongoing)S04046YYconfirmed PR6.0m (ongoing)S01030YYunconfirmed PRwithdrawn at 3.7m with progressionS01047YYunconfirmed PR4.8m (ongoing)
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-12-24.
Collapse
Affiliation(s)
- RD Baird
- University of Cambridge, Cambridge, United Kingdom; Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom; King's College London, Guy's Hospital, London, United Kingdom; Sarah Cannon Research UK, London, United Kingdom; University College London Cancer Institute, London, United Kingdom; Shionogi & Co. Ltd., Osaka, Japan
| | - N Cresti
- University of Cambridge, Cambridge, United Kingdom; Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom; King's College London, Guy's Hospital, London, United Kingdom; Sarah Cannon Research UK, London, United Kingdom; University College London Cancer Institute, London, United Kingdom; Shionogi & Co. Ltd., Osaka, Japan
| | - E Beddowes
- University of Cambridge, Cambridge, United Kingdom; Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom; King's College London, Guy's Hospital, London, United Kingdom; Sarah Cannon Research UK, London, United Kingdom; University College London Cancer Institute, London, United Kingdom; Shionogi & Co. Ltd., Osaka, Japan
| | - M Saggese
- University of Cambridge, Cambridge, United Kingdom; Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom; King's College London, Guy's Hospital, London, United Kingdom; Sarah Cannon Research UK, London, United Kingdom; University College London Cancer Institute, London, United Kingdom; Shionogi & Co. Ltd., Osaka, Japan
| | - M Flynn
- University of Cambridge, Cambridge, United Kingdom; Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom; King's College London, Guy's Hospital, London, United Kingdom; Sarah Cannon Research UK, London, United Kingdom; University College London Cancer Institute, London, United Kingdom; Shionogi & Co. Ltd., Osaka, Japan
| | - J Garcia Corbacho
- University of Cambridge, Cambridge, United Kingdom; Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom; King's College London, Guy's Hospital, London, United Kingdom; Sarah Cannon Research UK, London, United Kingdom; University College London Cancer Institute, London, United Kingdom; Shionogi & Co. Ltd., Osaka, Japan
| | - F Gao
- University of Cambridge, Cambridge, United Kingdom; Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom; King's College London, Guy's Hospital, London, United Kingdom; Sarah Cannon Research UK, London, United Kingdom; University College London Cancer Institute, London, United Kingdom; Shionogi & Co. Ltd., Osaka, Japan
| | - C Lemech
- University of Cambridge, Cambridge, United Kingdom; Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom; King's College London, Guy's Hospital, London, United Kingdom; Sarah Cannon Research UK, London, United Kingdom; University College London Cancer Institute, London, United Kingdom; Shionogi & Co. Ltd., Osaka, Japan
| | - K Donaldson
- University of Cambridge, Cambridge, United Kingdom; Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom; King's College London, Guy's Hospital, London, United Kingdom; Sarah Cannon Research UK, London, United Kingdom; University College London Cancer Institute, London, United Kingdom; Shionogi & Co. Ltd., Osaka, Japan
| | - J Posner
- University of Cambridge, Cambridge, United Kingdom; Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom; King's College London, Guy's Hospital, London, United Kingdom; Sarah Cannon Research UK, London, United Kingdom; University College London Cancer Institute, London, United Kingdom; Shionogi & Co. Ltd., Osaka, Japan
| | - I Kawabata
- University of Cambridge, Cambridge, United Kingdom; Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom; King's College London, Guy's Hospital, London, United Kingdom; Sarah Cannon Research UK, London, United Kingdom; University College London Cancer Institute, London, United Kingdom; Shionogi & Co. Ltd., Osaka, Japan
| | - M Forster
- University of Cambridge, Cambridge, United Kingdom; Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom; King's College London, Guy's Hospital, London, United Kingdom; Sarah Cannon Research UK, London, United Kingdom; University College London Cancer Institute, London, United Kingdom; Shionogi & Co. Ltd., Osaka, Japan
| | - HT Arkenau
- University of Cambridge, Cambridge, United Kingdom; Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom; King's College London, Guy's Hospital, London, United Kingdom; Sarah Cannon Research UK, London, United Kingdom; University College London Cancer Institute, London, United Kingdom; Shionogi & Co. Ltd., Osaka, Japan
| | - R Plummer
- University of Cambridge, Cambridge, United Kingdom; Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom; King's College London, Guy's Hospital, London, United Kingdom; Sarah Cannon Research UK, London, United Kingdom; University College London Cancer Institute, London, United Kingdom; Shionogi & Co. Ltd., Osaka, Japan
| | - D Jodrell
- University of Cambridge, Cambridge, United Kingdom; Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom; King's College London, Guy's Hospital, London, United Kingdom; Sarah Cannon Research UK, London, United Kingdom; University College London Cancer Institute, London, United Kingdom; Shionogi & Co. Ltd., Osaka, Japan
| | - J Spicer
- University of Cambridge, Cambridge, United Kingdom; Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom; King's College London, Guy's Hospital, London, United Kingdom; Sarah Cannon Research UK, London, United Kingdom; University College London Cancer Institute, London, United Kingdom; Shionogi & Co. Ltd., Osaka, Japan
| |
Collapse
|
9
|
Attard G, Olmos D, Arkenau HT, Ledaki I, Carden CP, Reid AH, Ang J, Fong PC, Parker C, De Bono JS. Pre- and post-treatment circulating tumor cell counts (CTCc) and overall survival (OS) in castration-resistant prostate cancer (CRPC): The Royal Marsden Hospital (RMH) experience. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.5072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
10
|
Nehls O, Okech T, Hsieh CJ, Enzinger T, Sarbia M, Borchard F, Gruenagel HH, Gaco V, Hass HG, Arkenau HT, Hartmann JT, Porschen R, Gregor M, Klump B. Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX. Br J Cancer 2007; 96:1409-18. [PMID: 17426704 PMCID: PMC2360187 DOI: 10.1038/sj.bjc.6603728] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
We evaluated the expression patterns of proapoptotic BAX, antiapoptotic Bcl-2 and p53, the proposed upstream effector of these molecules, as potential prognostic markers in UICC stage III colon cancer by immunohistochemical staining. To identify high-frequency microsatellite instability (MSI+) individuals, we performed single-strand conformation polymorphism-based analysis for BAT26. A total of 188 patients who had received 5-fluorouracil (5-FU)-based adjuvant chemotherapy (5-FU/folinic acid or 5-FU/levamisole) were enrolled. Median follow-up was 84.5 months. We found that BAX, Bcl-2 and p53 protein expressions were high or positive in 59, 70 and 50% of 188 cases, respectively. MSI+ tumours were detected in 9% of 174 evaluable patients. BAX or Bcl-2 was correlated with a higher degree of differentiation or left-sided tumours (P=0.01 or P=0.03, respectively); MSI was correlated with right-sided tumours (P<0.0001). In contrast to p53, Bcl-2, or MSI, low BAX, advanced pN category, low grade of differentiation and treatment with 5-FU/levamisole were univariately associated with poorer disease-free survival (DFS) (P=0.0005, P=0.001, P=0.005 and P=0.01, respectively) and poorer overall survival (OS) (P=0.002, P=0.0001, P=0.003 and P=0.02, respectively). Besides pN category and treatment arm, BAX was an independent variable related to both OS and DFS (P=0.003 and P=0.001, respectively). In both univariate and multivariate analysis, the p53−/BAX high in comparison with the p53+/BAX high subset conferred a significantly improved DFS (P=0.03 and P=0.03, respectively) as well as a marginally improved OS (P=0.07 and P=0.08, respectively). BAX protein expression may be of central significance for clinical outcome to 5-FU-based adjuvant chemotherapy in stage III colon cancer, and bivariate analysis of p53/BAX possibly may provide further prognostic evidence.
Collapse
Affiliation(s)
- O Nehls
- Department of Internal Medicine I, University Hospital, Tübingen, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Nehls O, Okech T, Hsieh CJ, Gaco V, Hass HG, Sarbia M, Borchard F, Gruenagel HH, Arkenau HT, Porschen R, Klump B. Major prognostic impact of proapoptotic BAX protein expression in stage III (UICC) colon cancer treated by adjuvant chemotherapy. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.9587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- O. Nehls
- Univ Hosp Tuebingen, Tuebingen, Germany; Dept of Pathology, TU München, München, Germany; Dept of Pathology, Hosp of Aschaffenburg, Aschaffenburg, Germany; Dept of Surg, Evangelic Hosp of Düsse, Düsseldorf, Germany; Clinic of Internal Medicine, Central Hosp Brem, Bremen, Germany
| | - T. Okech
- Univ Hosp Tuebingen, Tuebingen, Germany; Dept of Pathology, TU München, München, Germany; Dept of Pathology, Hosp of Aschaffenburg, Aschaffenburg, Germany; Dept of Surg, Evangelic Hosp of Düsse, Düsseldorf, Germany; Clinic of Internal Medicine, Central Hosp Brem, Bremen, Germany
| | - C.-J. Hsieh
- Univ Hosp Tuebingen, Tuebingen, Germany; Dept of Pathology, TU München, München, Germany; Dept of Pathology, Hosp of Aschaffenburg, Aschaffenburg, Germany; Dept of Surg, Evangelic Hosp of Düsse, Düsseldorf, Germany; Clinic of Internal Medicine, Central Hosp Brem, Bremen, Germany
| | - V. Gaco
- Univ Hosp Tuebingen, Tuebingen, Germany; Dept of Pathology, TU München, München, Germany; Dept of Pathology, Hosp of Aschaffenburg, Aschaffenburg, Germany; Dept of Surg, Evangelic Hosp of Düsse, Düsseldorf, Germany; Clinic of Internal Medicine, Central Hosp Brem, Bremen, Germany
| | - H. G. Hass
- Univ Hosp Tuebingen, Tuebingen, Germany; Dept of Pathology, TU München, München, Germany; Dept of Pathology, Hosp of Aschaffenburg, Aschaffenburg, Germany; Dept of Surg, Evangelic Hosp of Düsse, Düsseldorf, Germany; Clinic of Internal Medicine, Central Hosp Brem, Bremen, Germany
| | - M. Sarbia
- Univ Hosp Tuebingen, Tuebingen, Germany; Dept of Pathology, TU München, München, Germany; Dept of Pathology, Hosp of Aschaffenburg, Aschaffenburg, Germany; Dept of Surg, Evangelic Hosp of Düsse, Düsseldorf, Germany; Clinic of Internal Medicine, Central Hosp Brem, Bremen, Germany
| | - F. Borchard
- Univ Hosp Tuebingen, Tuebingen, Germany; Dept of Pathology, TU München, München, Germany; Dept of Pathology, Hosp of Aschaffenburg, Aschaffenburg, Germany; Dept of Surg, Evangelic Hosp of Düsse, Düsseldorf, Germany; Clinic of Internal Medicine, Central Hosp Brem, Bremen, Germany
| | - H.-H. Gruenagel
- Univ Hosp Tuebingen, Tuebingen, Germany; Dept of Pathology, TU München, München, Germany; Dept of Pathology, Hosp of Aschaffenburg, Aschaffenburg, Germany; Dept of Surg, Evangelic Hosp of Düsse, Düsseldorf, Germany; Clinic of Internal Medicine, Central Hosp Brem, Bremen, Germany
| | - H. T. Arkenau
- Univ Hosp Tuebingen, Tuebingen, Germany; Dept of Pathology, TU München, München, Germany; Dept of Pathology, Hosp of Aschaffenburg, Aschaffenburg, Germany; Dept of Surg, Evangelic Hosp of Düsse, Düsseldorf, Germany; Clinic of Internal Medicine, Central Hosp Brem, Bremen, Germany
| | - R. Porschen
- Univ Hosp Tuebingen, Tuebingen, Germany; Dept of Pathology, TU München, München, Germany; Dept of Pathology, Hosp of Aschaffenburg, Aschaffenburg, Germany; Dept of Surg, Evangelic Hosp of Düsse, Düsseldorf, Germany; Clinic of Internal Medicine, Central Hosp Brem, Bremen, Germany
| | - B. Klump
- Univ Hosp Tuebingen, Tuebingen, Germany; Dept of Pathology, TU München, München, Germany; Dept of Pathology, Hosp of Aschaffenburg, Aschaffenburg, Germany; Dept of Surg, Evangelic Hosp of Düsse, Düsseldorf, Germany; Clinic of Internal Medicine, Central Hosp Brem, Bremen, Germany
| |
Collapse
|
12
|
Arkenau HT, Rettig K, Porschen R. Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion. Int J Colorectal Dis 2005; 20:258-61. [PMID: 15549327 DOI: 10.1007/s00384-004-0657-6] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 07/26/2004] [Indexed: 02/04/2023]
Abstract
BACKGROUND Adjuvant postoperative treatment with 5-fluorouracil (5-FU) and leucovorin in curatively resected stage III colon cancer significantly reduces the risk of cancer recurrence and improves survival. The impact of continuous 5-FU with and without leucovorin on survival and tumor recurrence was analyzed in this study compared with the effects of bolus 5-FU/leucovorin. PATIENTS AND METHODS Patients with a curatively resected UICC stage III colon cancer were stratified according to T, N and G category and randomly assigned to receive one of the three adjuvant treatment schemes: 5-FU 450 mg/m2 and leucovorin 100 mg/m2 x 5 days every 4 weeks; six cycles, arm A; 24-h infusion of high-dose 5-FU/leucovorin 2,600 mg/m2 and 500 mg/m2, two cycles of six applications, arm B; 24-h infusion of high-dose 5-FU 2,600 mg/m2, two cycles of six applications, arm C. RESULTS One hundred and forty-five patients enrolled into this study were eligible. To date, 28 patients have died; 9 on arm A, 11 on arm B, and 8 on arm C (P was nonsignificant). After a median follow-up time of 45 months, there was no statistical difference in survival and tumor recurrence between the three treatment arms. Adjuvant treatment in all arms was generally well tolerated; only a minority of patients experienced grade 3 and 4 toxicities. CONCLUSION There is no statistical difference in efficacy and toxicity in patients receiving either high-dose 5-FU with or without leucovorin or the standard 5-FU bolus regime after a curative resection of a stage III colon cancer.
Collapse
Affiliation(s)
- H T Arkenau
- Clinic of Internal Medicine, Hospital Bremen East, Züricher Strasse 40, 28325 Bremen, Germany
| | | | | |
Collapse
|
13
|
Arkenau HT, Schmoll HJ, Kubicka S, Seufferlein T, Reichardt P, Freier W, Graeven U, Grothey A, Porschen R. Phase III trial of infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of advanced colorectal carcinoma (ACRC): results of an interim safety analysis. Z Gastroenterol 2004. [DOI: 10.1055/s-2004-831656] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
14
|
Arkenau HT, Bermann A, Rettig K, Strohmeyer G, Porschen R. 5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial. Ann Oncol 2003; 14:395-9. [PMID: 12598344 DOI: 10.1093/annonc/mdg100] [Citation(s) in RCA: 63] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Adjuvant postoperative treatment with 5-fluorouracil (5-FU) and leucovorin in curatively resected stage III colon cancer significantly reduces the risk of cancer recurrences and improves survival. The impact of 5-FU plus leucovorin on survival and tumor recurrence was analyzed in a long-term follow-up study in comparison with the effects of 5-FU plus levamisole in the prospective multicenter trial adjCCA-01. PATIENTS AND METHODS Patients with a curatively resected stage III (International Union Against Cancer) colon cancer were stratified according to tumor, node and grading category and randomly assigned to receive one of the two adjuvant treatment schemes: 5-FU 400 mg/m2 body surface area intravenously in the first chemotherapy course, then 450 mg/m2 x 5 days, plus leucovorin 100 mg/m2, 12 cycles (arm A), or 5-FU plus levamisole (Moertel scheme; arm B). RESULTS Six hundred and eighty (96.9%) of 702 patients enrolled into this study were eligible. To date, 261 patients have died, 117 on arm A and 144 on arm B (P = 0.007). After a median follow-up time of 82 months, the 5-FU plus leucovorin combination significantly improved disease-free survival [79.8 months in arm A versus 69.3 months in arm B (P = 0.012)] and significantly increased median overall survival (88.9 months in arm A versus 78.6 months in arm B; P = 0.003). Adjuvant treatment with 5-FU plus levamisole as well as 5-FU plus leucovorin was generally well tolerated; only a minority of patients experienced grade 3 and 4 toxicities. CONCLUSIONS After curative resection of a stage III colon cancer, adjuvant treatment with 5-FU plus leucovorin is generally well tolerated. This long-term follow-up study demonstrates that adjuvant treatment with 5-FU plus leucovorin given for 12 cycles is significantly more effective than 5-FU plus levamisole (Moertel scheme) in reducing tumor relapse and improving survival.
Collapse
Affiliation(s)
- H T Arkenau
- Clinic of Internal Medicine, Central Hospital Bremen East, Bremen, Germany
| | | | | | | | | |
Collapse
|
15
|
Arkenau HT, Stichtenoth DO, Frölich JC, Manns MP, Böker KHW. Elevated nitric oxide levels in patients with chronic liver disease and cirrhosis correlate with disease stage and parameters of hyperdynamic circulation. Z Gastroenterol 2002; 40:907-13. [PMID: 12436367 DOI: 10.1055/s-2002-35413] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Chronic liver diseases are accompanied by changes in splanchnic and systemic circulation. These changes are characterised by a reduction in peripheral vascular resistance and an increased cardiac output at rest. An increased release of nitric oxide (NO) has been proposed to play a role in the pathogenesis of vasodilatation and vascular hypocontractility. This study was designed to determine the nitric oxide metabolism measured as circulating nitrate levels in serum/urine in patients with chronic liver disease and cirrhosis. The nitrate concentrations were significantly increased in advanced degrees in cirrhosis Child B and C, and normal or even reduced in patients with chronic active hepatitis and early cirrhosis. In our study the connections between the extent of portal hypertension and nitrate levels were evident. The presence of ascites as well as the the progression of oesophageal varices were associated with higher circulating nitrate levels. The connection between increased nitric oxide production and the haemodynamic sequelae of portal hypertension is also apparent in the significant correlation between plasma renin and serum nitrate levels. Circulating nitrate levels also correlated to the serum interleukin-6 levels. This study demonstrated that the increased nitric oxide metabolism is associated with the haemodynamic alterations induced by portal hypertension.
Collapse
Affiliation(s)
- H T Arkenau
- Klinik für Innere Medizin, Zentralkrankenhaus Bremen Ost, Germany.
| | | | | | | | | |
Collapse
|
16
|
Nehls O, Klump B, Arkenau HT, Hass HG, Greschniok A, Gregor M, Porschen R. Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. Br J Cancer 2002; 87:702-4. [PMID: 12232749 PMCID: PMC2364257 DOI: 10.1038/sj.bjc.6600543] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2002] [Accepted: 07/15/2002] [Indexed: 11/09/2022] Open
Abstract
We studied the activity of combined oxaliplatin and fluorouracil-leucovorin in 16 consecutive patients with advanced biliary tract adenocarcinomas. The disease control rate (responses and stable disease) was 56% (95% confidence interval, 29-84%) and the median overall survival time was 9.5 months (range 0.9-26.8+). Therefore, this regimen might be active in biliary adenocarcinomas with further evaluation necessary.
Collapse
Affiliation(s)
- O Nehls
- Department of Internal Medicine I, University Hospital, Otfried-Müller-Str. 10, 72076 Tübingen, Germany.
| | | | | | | | | | | | | |
Collapse
|
17
|
Arkenau HT, Hegglin I, Lüthi U. [Trichosporosis]. Schweiz Med Wochenschr 2000; 130:1914. [PMID: 11153398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Affiliation(s)
- H T Arkenau
- Pathologisches Institut und Medizinische Klinik, Kantonsspital Luzern
| | | | | |
Collapse
|
18
|
Arkenau HT, Lüthi U. [Amyloidoma]. Schweiz Med Wochenschr 2000; 130:1244. [PMID: 11013930] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Affiliation(s)
- H T Arkenau
- Pathologisches Institut, Kantonsspital Luzern
| | | |
Collapse
|